Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARTSCAN VI Protocol Version 1, 2023-07-03 ARTSCAN VI - a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients

NCT06248996 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT06248996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06248996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARTSCAN VI Protocol Version 1, 2023-07-03 ARTSCAN VI - a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients
Lead sponsor
Lund University Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
March 4, 2024
Completion date
March 4, 2033
Enrollment
308 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma